TAIPEI, July 28, 2015 /PRNewswire/ -- TWi Pharmaceuticals, Inc. today announced that it launched its generic version of Par Pharmaceutical's MEGACE ES® (megestrol acetate oral suspension) 625mg/5ml ...
TWi Pharmaceuticals, Inc. today announced that it launched its generic version of Par Pharmaceutical's MEGACE ES® (megestrol acetate oral suspension) 625mg/5ml after the United States District Court ...
WOODCLIFF LAKE, N.J., Oct. 14, 2011 /PRNewswire via COMTEX/ -- Par Pharmaceutical, Inc., the wholly-owned subsidiary of Par Pharmaceutical Companies, Inc. today announced that it filed a declaratory ...
March 5 (Reuters) - Par Pharmaceutical Cos, a generic drugmaker, has pleaded guilty to improperly marketing a medication intended to address appetite loss in AIDS patients, and agreed to pay $45 ...
NEWARK (CN) – Par Pharmaceuticals pleaded guilty and will pay $45 million in criminal and civil fines for promoting its anorexia drug Megace ES for off-label uses, federal prosecutors said. Doctors ...
LONDON (MarketWatch) -- Par Pharmaceutical Companies said it's won Food and Drug Administration approval for Megace ES, a treatment for anorexia, cachexia or AIDS-related weight loss. Par said Megace ...
Megestrol acetate 125mg/mL; lemon flavor. Several investigators have reported on the appetite enhancing property of megestrol acetate and its possible use in cachexia. The precise mechanism by which ...
Law360 (March 30, 2009, 12:00 AM EDT) -- The U.S. Department of Justice has launched an investigation into Par Pharmaceutical Cos. Inc.'s promotional practices for its appetite enhancer Megace ES, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results